000			03788nam a22003975i 4500
999			_c11246 _d11246
001			11246
003			DE-He213
005			20210706040345.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180529s2018 gw | s |||| 0|eng d
020			_a9783319781549
024	7		_a10.1007/978-3-319-78154-9 _2doi
040			_aES-MaUEC _bspa _dES-MaUEC
050		4	_aRC270.8 _b.I56 2018 EB
245	1	0	_aInnovations for Next-Generation Antibody-Drug Conjugates _cedited by Marc Damelin.
264		1	_aCham _bSpringer International Publishing : _bImprint: Humana Press _c2018.
300			_a1 recurso en línea (VIII, 357 páginas 70 ilustraciones, 52 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCancer Drug Discovery and Development _x2196-9906
490	0		_aMedicine (Springer-11650)
505	0		_aChapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology.
520	3		_aAntibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
650		7	_aOncología _9139207 _2embne
650		7	_aCáncer _xTratamiento _9174085 _2embne
700	1		_aDamelin, Marc. _eeditor literario
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319781532
776	0	8	_iEdición impresa: _z9783319781556
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-78154-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db